# Why our investors joined Sempresto | Sempresto

- Canonical URL: https://wefunder.com/feed/437699
- Entity ID: wefunder:feed_item:437699
- Published at: 2026-10-27 15:19:49 UTC
- Updated at: 2026-10-27 15:35:48 UTC

## Author
Elizabeth Reczek

## Subject
Sempresto

## Content
As we near the closing of our round, I wanted to share why some of our investors have chosen to back Sempresto.From angel investor Dominic J. Frederico, who committed $2.6M to lead our round: "Sempresto is addressing a clear and important unmet need with an elegant and highly practical solution that has the potential to improve and save lives."George Graham Smith III of QuakerSmith Capital, who invested $100,000: "For me, the company checks all the boxes: robust product design, strong patent position, high unmet need, clear path to market, solid prospects for commercial success, and a highly qualified management team."Since we opened this round to the community, we have heard from many people in the allergy community about how hard it can be to keep epinephrine on hand. That unmet need is why we are developing Sempresto.Join professional and retail investors who have invested in this round: wefunder.com/semprestoLizElizabeth Reczek, PhDCo-Founder & CEO, SemprestoSempresto is an investigational product. It has not been approved by the FDA and is not available for sale.